Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02657408
Recruitment Status : Completed
First Posted : January 15, 2016
Results First Posted : July 10, 2019
Last Update Posted : July 10, 2019
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Tracking Information
First Submitted Date  ICMJE January 14, 2016
First Posted Date  ICMJE January 15, 2016
Results First Submitted Date  ICMJE December 17, 2018
Results First Posted Date  ICMJE July 10, 2019
Last Update Posted Date July 10, 2019
Actual Study Start Date  ICMJE March 11, 2016
Actual Primary Completion Date February 14, 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 18, 2019)
Total Cell Count of Neutrophils in Bronchoalveolar Lavage (BAL) Fluid After 24 Hours of the Segmental Lipopolysaccharide (LPS) Challenge [ Time Frame: Day 29 ]
Total cell count of neutrophils in Bronchoalveolar Lavage (BAL) fluid after 24 hours of the segmental Lipopolysaccharide (LPS) challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the Least Square (LS) means obtained by fitting an Analysis of variance (ANOVA) model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method.
Original Primary Outcome Measures  ICMJE
 (submitted: January 14, 2016)
Total cell count of neutrophils in Bronchoalveolar Lavage (BAL) after 24 hours of the segmental endotoxin challenge [ Time Frame: Day 29 ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 18, 2019)
  • Differential Cell Count of Neutrophils in BAL Fluid 24 h After Segmental LPS Challenge. [ Time Frame: Day 29 ]
    Differential cell count of neutrophils in BAL fluid 24 h after segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method.
  • Total Cell Count of Eosinophil in BAL Fluid After 24 Hours of the Segmental LPS Challenge [ Time Frame: Day 29 ]
    Total cell count of eosinophil in BAL fluid after 24 hours of the segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method.
  • Differential Cell Count of Eosinophil in BAL Fluid 24 h After Segmental LPS Challenge. [ Time Frame: Day 29 ]
    Differential cell count of eosinophil in BAL fluid 24 h after segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method.
  • Total Cell Count of Monocyte in BAL Fluid After 24 Hours of the Segmental LPS Challenge [ Time Frame: Day 29 ]
    Total cell count of monocyte in BAL fluid after 24 hours of the segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method. Monocyte cell count is the only cell count which was assessed by means of flow cytometry.
  • Differential Cell Count of Monocyte in BAL Fluid 24 h After Segmental LPS Challenge. [ Time Frame: Day 29 ]
    Differential cell count of monocyte (determined by flow cytometry) in BAL fluid 24 h after segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method. Monocyte cell count is the only cell count which was assessed by means of flow cytometry.
  • Total Cell Count of Macrophage+Monocyte in BAL Fluid After 24 Hours of the Segmental LPS Challenge [ Time Frame: Day 29 ]
    Total cell count of macrophage+monocyte BAL fluid after 24 hours of the segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method. Cytospin microscopy method cannot clearly differentiate between macrophages and monocytes, the total and differential cell count of macrophages and monocytes are presented together.
  • Differential Cell Count of Macrophage+Monocyte in BAL Fluid 24 h After Segmental LPS Challenge. [ Time Frame: Day 29 ]
    Differential cell count of macrophage+monocyte in BAL fluid 24 h after segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method. Cytospin microscopy method cannot clearly differentiate between macrophages and monocytes, the total and differential cell count of macrophages and monocytes are presented together.
  • Total Cell Count of Lymphocyte in BAL After 24 Hours of the Segmental LPS Challenge [ Time Frame: Day 29 ]
    Total cell count of lymphocyte after 24 hours of the segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method.
  • Differential Cell Count of Lymphocyte in BAL Fluid 24 h After Segmental LPS Challenge. [ Time Frame: Day 29 ]
    Differential cell count of lymphocyte in BAL fluid 24 h after segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method.
Original Secondary Outcome Measures  ICMJE
 (submitted: January 14, 2016)
  • Total and differential cell count of neutrophils (only differential cell count) in BAL after 24 hours of the segmental endotoxin challenge [ Time Frame: Day 29 ]
  • Total and differential cell count of eosinophils in BAL after 24 hours of the segmental endotoxin challenge [ Time Frame: Day 29 ]
  • Total and differential cell count of monocytes in BAL after 24 hours of the segmental endotoxin challenge [ Time Frame: Day 29 ]
  • Total and differential cell count of macrophages in BAL after 24 hours of the segmental endotoxin challenge [ Time Frame: Day 29 ]
  • Total and differential cell count of lymphocytes in BAL after 24 hours of the segmental endotoxin challenge [ Time Frame: Day 29 ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo
Official Title  ICMJE A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase I Trial in Healthy Male Current Smoker Subjects to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response and Safety of 4 Weeks Oral Administration of BI 1026706
Brief Summary The primary and secondary objectives of the current study are the assessments of anti-inflammatory pharmacodynamic effects on segmental endotoxin induced inflammatory response after 4 weeks treatment with BI 1026706.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Healthy
Intervention  ICMJE
  • Drug: BI 1026706
  • Drug: Placebo
Study Arms  ICMJE
  • Experimental: BI 1026706
    Intervention: Drug: BI 1026706
  • Experimental: Placebo
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 10, 2017)
57
Original Estimated Enrollment  ICMJE
 (submitted: January 14, 2016)
50
Actual Study Completion Date  ICMJE March 13, 2017
Actual Primary Completion Date February 14, 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion criteria:

  • Signed informed consent consistent with ICH-Good Clinical Practice (GCP) guidelines and local legislation prior to participation in the trial.
  • Healthy volunteers of both sex between 18 and 65 years (inclusive) of age, on the day of subject's signature of informed consent.
  • Healthy subjects as assessed by the investigator, based on a screening examination including medical history, physical examination, vital signs (blood pressure, pulse rate, body temperature), 12-lead ECG, lung function and clinical laboratory results.
  • Forced expiratory volume (FEV1) of >80% and FEV1/Forced vital capacity(fFVC) of >70% of the predicted normal value at screening
  • Current smokers with a smoking history of at least 1 pack year and with at least 1 cigarette per day in the previous year
  • BMI (Body mass index) range: >18.5 and < 29.9kg/m2.
  • Negative urine drug screening.
  • Negative breath alcohol test.
  • Negative skin prick test (performed within the 12 months prior to study start or at study start)
  • Females NOT of childbearing potential are defined as: Women who are postmenopausal (12 months with no menses without an alternative medical cause; in questionable cases a blood sample with simultaneous levels of FSH above 40 U/L and estradiol below 30 ng/L is confirmatory) or who are permanently sterilized (defined as hysterectomy, bilateral oophorectomy or bilateral salpingectomy).
  • Further inclusion criteria apply

Exclusion criteria:

  • History of any relevant lung disease (i.e. Chronic Obstructive Pulmonary Disease (COPD), asthma, chronic bronchitis, pulmonary fibrosis, pulmonary alveolar proteinosis (PAP), pneumocystis infection, active tuberculosis, silicosis or any other lung surfactant overproduction syndromes).
  • Subjects with clinically relevant abnormal hematology, blood chemistry, or urinalysis at the screening visit
  • Any finding of the medical examination (including blood pressure, pulse rate, body temperature and ECG) deviating from normal and of clinical relevance.
  • Subjects with a history of any clinically significant cardiovascular, metabolic, renal (including renal stones), hepatic, gastrointestinal, hematological, dermatological, venereal, neurological, psychiatric or other major disorders.
  • Subjects with a malignancy for which the subject has undergone resection, radiation therapy or chemotherapy within the last five years. Subjects with treated basal cell carcinoma or fully cured squamous cell carcinoma are allowed to participate.
  • Subjects with previous surgery of the gastro-intestinal tract likely to affect drug absorption.
  • History of relevant orthostatic hypotension, fainting spells or blackouts.
  • Subjects with clinically relevant infection or known ongoing clinically relevant inflammatory process.
  • History of relevant allergy/hypersensitivity including allergy to drug or its excipients or medications in line with bronchoscopy (bronchodilators, sedatives and local anesthetics).
  • Subjects with a marked baseline prolongation of QT/QTcB interval (such as repeated demonstration of a QTcB interval >450 ms), or any other relevant ECG finding at screening visit (Visit 1) according to the investigator.
  • Neutrophil blood count indicative of immunosuppression according to the investigator at screening visit (Visit 1).
  • Subjects with previous surgeries that may have left ferromagnetic material in the body, ferromagnetic implants or pacemakers.
  • Participation in another study with any investigational product within 2 months prior to screening or if screening occurs within 6 half-lives of intake of another investigational drug (whichever is greater).
  • Male subjects who do not agree to minimize the risk of female partners becoming pregnant from the first dosing day until 3 months after the trial medication treatment has finished.
  • Subjects who are committed to an institution by way of official or juridical order will not be enrolled in the trial.
  • Receipt of live (attenuated) vaccine within the 4 weeks prior to screening or during the trial.
  • Subject is assessed as unsuitable for inclusion by the investigator; for instance, because he is not considered able to understand and comply with study requirements or has a condition that would not allow safe participation in the study.
  • For female subjects:

    • Positive pregnancy test at screening Visit 1, pregnancy or plans to become pregnant within 30 days after study completion
    • Lactation
  • Further exclusion criteria apply
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE Child, Adult, Older Adult
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Germany
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02657408
Other Study ID Numbers  ICMJE 1320.17
2015-001789-25 ( EudraCT Number )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Boehringer Ingelheim
Study Sponsor  ICMJE Boehringer Ingelheim
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
PRS Account Boehringer Ingelheim
Verification Date April 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP